Anthony Quinn, 49 and from Pity Me, has now been given a groundbreaking new treatment called Produodopa. Anthony becomes one of the first people in England to receive this outside of specialist ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

What you need to know about the new rulesPatients with Parkinson's disease get zero benefit from taking a skinny jab despite ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.